Deepnoid Accelerates Shift in Medical AI Paradigm

Multimodal Generative AI-Based Solution "M4CXR"

On September 9, Deepnoid, a leading first-generation medical artificial intelligence (AI) company in Korea, announced that it will accelerate the shift in the medical AI paradigm by promoting the commercialization of its multimodal generative AI-based medical device, "M4CXR."

M4CXR is a generative AI-powered chest X-ray interpretation solution that can analyze 41 types of lesions within seconds and automatically generate a draft of the interpretation report. Last month, it received approval for its clinical trial plan from the Ministry of Food and Drug Safety and is currently conducting multi-center clinical trials. The company has entered the initial phase for commercialization.

Existing solutions based on unimodal technology were limited to detecting the presence of lesions and suspicious areas. M4CXR automatically drafts interpretation reports at a level that can be directly utilized in real clinical settings. By providing practical utility that medical professionals can immediately reference in patient care, it is attracting significant attention in the industry for its efficient support of radiological interpretation.

M4CXR applies multimodal learning to simultaneously analyze images and text, enabling a comprehensive understanding of the context within X-ray images.

Rather than simply listing disease names, M4CXR generates detailed and professional draft interpretation reports similar to those written by actual physicians. By training on a dataset of more than 10 million chest X-rays and interpretation reports, it can accurately interpret even rare diseases and complex cases. It is expected to greatly enhance the diagnostic efficiency of healthcare professionals and the reliability of patient care.

Choi Woosik, CEO of Deepnoid, stated, "Generative AI-based medical imaging diagnostic technology is an innovative solution that simultaneously improves both the accuracy and accessibility of healthcare," and added, "With the commercialization of M4CXR, Deepnoid will further solidify its technological leadership."

Deepnoid is also developing new solutions that expand the learning scope to CT images, thereby broadening its diagnostic support capabilities. The company expects to secure AI-based diagnostic technologies that can be utilized in various clinical environments.

By integrating its proprietary remote interpretation system with its medical AI solutions, Deepnoid will introduce a "total AI interpretation service platform." This system, which integrates the entire remote interpretation process, aims to enhance the work efficiency of medical professionals, with development targeted for completion in the first half of next year.

This content was produced with the assistance of AI translation services.